Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Convertible Debt (2016 - 2020)

Historic Convertible Debt for Zevra Therapeutics (ZVRA) over the last 6 years, with Q4 2020 value amounting to $67.7 million.

  • Zevra Therapeutics' Convertible Debt fell 1252.21% to $67.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $67.7 million, marking a year-over-year decrease of 1252.21%. This contributed to the annual value of $67.7 million for FY2020, which is 1252.21% down from last year.
  • Per Zevra Therapeutics' latest filing, its Convertible Debt stood at $67.7 million for Q4 2020, which was down 1252.21% from $77.3 million recorded in Q4 2019.
  • Zevra Therapeutics' 5-year Convertible Debt high stood at $90.8 million for Q3 2016, and its period low was $67.7 million during Q4 2020.
  • Moreover, its 4-year median value for Convertible Debt was $82.5 million (2018), whereas its average is $81.6 million.
  • In the last 5 years, Zevra Therapeutics' Convertible Debt soared by 111853.1% in 2016 and then tumbled by 1906.37% in 2019.
  • Over the past 4 years, Zevra Therapeutics' Convertible Debt (Quarter) stood at $90.8 million in 2016, then decreased by 13.96% to $78.1 million in 2018, then decreased by 0.98% to $77.3 million in 2019, then dropped by 12.52% to $67.7 million in 2020.
  • Its Convertible Debt was $67.7 million in Q4 2020, compared to $77.3 million in Q4 2019 and $70.6 million in Q3 2019.